Mr GP Singh will have an overall responsibility for the operations under Jubilant Pharma and will report to the Jubilant Pharma Board. He will be based in the United States. Prior to Jubilant, Mr Singh had served as president of Sun Pharmaceuticals, USA and contributed to the growth of Sun's US business. He has worked extensively both in India and in the US in various leadership roles pertaining to Strategy, M&A, Commercial and Operations.
The appointment of Mr Singh as CEO of Jubilant Pharma strengthens the management structure of the company and follows the appointment of Mr Pramod Yadav and Mr Rajesh Srivastava as co-CEOs of the Life Science Ingredients business of Jubilant Life Sciences.
Commenting on the appointment of Mr Singh, Mr Shyam S Bhartia, chairman and managing director and Mr Hari S Bhartia, co- chairman and managing director, Jubilant Life Sciences said, "We are pleased to welcome Mr Singh into the Jubilant family to complete our pharma consolidation. Our Pharmaceuticals segment has attained significant scale and the businesses therein have great potential for growth. Mr. Singh's rich experience in Pharmaceuticals industry will help the company to enhance its focus and competitiveness thereby unlocking shareholder value."